Asymchem revenue climbed past RMB 10 billion in 2022, then fell for two straight years. Here's what drove the swing and what it means for buyers.
Asymchem Laboratories (Tianjin) Co., Ltd. reported revenue of roughly RMB 5.8 billion in 2024, down from a peak of about RMB 10.3 billion in 2022. Asymchem is a China-based contract development and manufacturing organization, or CDMO, that makes active pharmaceutical ingredients and intermediates for other drug companies. Its revenue rises and falls with a small number of very large manufacturing contracts, not with retail demand for research peptides.
All figures below are rounded from the company's published annual results, and the currency is Chinese renminbi (RMB). Investors should confirm exact numbers in the latest annual report or exchange filing before making any decision.
Asymchem Revenue by Year at a Glance
| Fiscal year | Approx. revenue | What mainly drove it |
|---|---|---|
| 2021 | ~RMB 4.6 billion | Base small-molecule CDMO business |
| 2022 | ~RMB 10.3 billion | One outsized commercial API contract |
| 2023 | ~RMB 7.8 billion | Large contract winds down; base business holds steady |
| 2024 | ~RMB 5.8 billion | Pricing pressure and soft biotech funding |
Asymchem's revenue roughly doubled in 2022 and then declined for two consecutive years. That pattern is unusual for a CDMO and reflects how concentrated the company's order book became during the pandemic.
Why Asymchem's Revenue Spiked in 2022
The 2022 jump came from a single large commercial manufacturing contract, widely reported to be tied to a COVID-19 antiviral API. When one customer orders at that scale, revenue can double in a year without the underlying business changing much.
Three consequences followed:
- Customer concentration. A handful of buyers accounted for a very large share of sales.
- Tougher comparisons. Once the big order shipped, year-over-year growth turned negative.
- Margin pressure. Utilization fell as capacity built for that order sat partly idle.
Asymchem is now trying to replace that revenue with a broader base of small-molecule, peptide, and oligonucleotide programs. Many of those programs sit in early clinical phases, which means they convert into revenue slowly.
What Drives Asymchem Revenue Today
Asymchem earns most of its revenue from long-term development and manufacturing contracts with pharmaceutical and biotech companies. The mix looks roughly like this:
- Small-molecule APIs and intermediates, including late-phase and commercial supply.
- Peptide and oligonucleotide manufacturing for drug developers, not for consumer resale.
- Clinical-stage services, where asymchem clinical support covers process development, scale-up, and trial material supply.
- US and European operations, which let Western customers keep part of the supply chain outside China.
Policy risk matters here too. US legislative proposals aimed at limiting reliance on Chinese CDMOs have pressured valuations across the whole sector, including for companies not named in those bills.
Asymchem Laboratories: Company Basics
Asymchem Laboratories was founded in 1998 and is headquartered in Tianjin, China. Its shares trade on the Shenzhen Stock Exchange under ticker 002821 and on the Hong Kong Stock Exchange under 6821.
Details about asymchem china location, including manufacturing sites in several provinces and research operations in Shanghai, are disclosed in the company's annual report and investor presentations. Asymchem also operates outside China, having acquired a US-based process chemistry business to serve North American clients.
Anyone reading asymchem reviews will notice two very different conversations. Investors debate order flow, capacity utilization, and margin recovery, while peptide buyers argue about whether a vendor's claimed supplier is real.
Why Peptide Buyers Search for Asymchem
Some US peptide vendors list Asymchem as the manufacturer behind their products. That claim is hard for a retail buyer to verify, and Asymchem itself does not run a consumer storefront.
Asymchem is a business-to-business manufacturer and does not sell BPC-157 or other research peptides directly to US consumers. If a website suggests otherwise, treat the marketing with caution and ask for documentation.
Practical steps before buying from any peptide supplier:
- Request a current certificate of analysis with a lot number and third-party test results.
- Ask for the full legal name and address of the manufacturer, not just a brand name.
- Check whether the vendor publishes purity data from an accredited laboratory.
- Read the handling instructions, since questions like how to store bpc 157 are answered by stability data rather than forum posts.
None of this is medical advice. Research peptides sold online are not FDA-approved for human use, and anyone considering them for a health reason should speak with a licensed healthcare professional first.
How to Track Asymchem Revenue Going Forward
- Quarterly reports. Revenue is lumpy, so compare quarters year over year rather than sequentially.
- Order announcements. Large contract awards usually move forecasts before they move reported sales.
- Contract liabilities and backlog. These hint at work that is booked but not yet billed.
- Segment mix. Growth in peptide and oligonucleotide work signals diversification away from one dominant customer.
The key takeaway is that Asymchem's revenue story is a concentration story. When one giant contract lands, revenue spikes, and when that contract ends, the base business has to carry the load.
Frequently Asked Questions
What is Asymchem's annual revenue?
Asymchem reported roughly RMB 5.8 billion in revenue for fiscal 2024, down from about RMB 10.3 billion in 2022. The company publishes exact figures in its annual and quarterly filings with the Shenzhen and Hong Kong stock exchanges. Revenue has fallen for two straight years as a large COVID-era manufacturing contract rolled off.
Is Asymchem a Chinese company?
Yes. Asymchem Laboratories was founded in 1998 and is headquartered in Tianjin, China, with manufacturing and research sites across the country. Its shares trade on the Shenzhen Stock Exchange under 002821 and on the Hong Kong Stock Exchange under 6821.
Does Asymchem sell peptides or BPC-157 to consumers in the US?
No. Asymchem is a contract development and manufacturing organization that supplies pharmaceutical and biotech companies under commercial agreements, not a retail peptide seller. Any US vendor claiming to ship Asymchem peptides to individual buyers should be asked for a certificate of analysis and a verifiable manufacturer name. Research peptides sold online are not FDA-approved for human use.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.